
May 30 (Reuters) - Merck & Co Inc MRK.N:
MERCK’S INVESTIGATIONAL ZILOVERTAMAB VEDOTIN AT 1.75 MG/KG DOSE PLUS STANDARD OF CARE SHOWED PROMISING ANTITUMOR ACTIVITY, INCLUDING COMPLETE RESPONSE RATE, IN PATIENTS WITH RELAPSED/REFRACTORY DLBCL IN PHASE 2 PORTION OF WAVELINE-003 TRIAL
MERCK & CO INC - ZILOVERTAMAB VEDOTIN ACHIEVES 56.3% ORR IN RELAPSED/REFRACTORY DLBCL
MERCK & CO INC - ZILOVERTAMAB VEDOTIN UNDER EVALUATION IN PHASE 3 AND PHASE 2 STUDIES